<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4288721</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P68</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P68</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Wang-Gillam</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Picozzi</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Crocenzi</surname><given-names>Todd</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Morse</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Zeh</surname><given-names>Herbert</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Fine</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Murphy</surname><given-names>Aimee</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Skoble</surname><given-names>Justin</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Lemmens</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Ferber</surname><given-names>Sandy</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Rosen</surname><given-names>Allan</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Grous</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Dubensky</surname><given-names>Thomas W</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" corresp="yes" id="A14"><name><surname>Brockstedt</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Jaffee</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Le</surname><given-names>Dung</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib></contrib-group><aff id="I1"><label>1</label>Washington University School of Medicine in St. Louis, St. Louis, MO, USA</aff><aff id="I2"><label>2</label>Virginia Mason Medical Center, Seattle, WA, USA</aff><aff id="I3"><label>3</label>Earle A. Chiles Research Institute, Portland, OR, USA</aff><aff id="I4"><label>4</label>Duke University Medical Center, Durham, NC, USA</aff><aff id="I5"><label>5</label>University of Pittsburgh Medical Center, Pittsburgh, PA, USA</aff><aff id="I6"><label>6</label>Columbia University, New York, NY, USA</aff><aff id="I7"><label>7</label>Aduro BioTech, Inc., Berkeley, CA, USA</aff><aff id="I8"><label>8</label>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P68</fpage><lpage>P68</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Wang-Gillam et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Wang-Gillam et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P68"/><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec><title>Background</title><p>A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with metastatic pancreatic adenocarcinoma (PDA). GVAX is composed of lethally-irradiated, allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated <italic>Listeria monocytogenes </italic>engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. In a recently completed Phase II study, the CY/GVAX plus CRS-207 combination resulted in statistically-significant improvement of overall survival (OS) compared to CY/GVAX alone (Le, GI ASCO 2014).</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a Phase IIb study comparing CY/GVAX and CRS-207 to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic PDA. Subjects will be enrolled in two cohorts: 150 subjects into a primary cohort of patients with at least two prior treatment regimens for metastatic disease (3<sup>rd</sup>+ line) and 90 subjects into an exploratory cohort of patients with only one prior treatment regimen for metastatic disease (2<sup>nd </sup>line). Subjects will be randomized in a 1:1:1 ratio to receive either 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm A), 6 doses of CRS-207 (Arm B) or physician's choice of select single-agent chemotherapy (Arm C). The primary objective is to compare OS in the primary cohort between Arms A and C. Secondary/exploratory objectives include: comparison of OS in both primary and exploratory cohorts between all treatment arms, assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of <italic>Lm- </italic>and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response. (Sponsor: Aduro BioTech, Inc.; NCT02004262).</p></sec></body></article>